Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more
Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on... read more
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more
PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more
The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more
Peabody, MA – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug... read more
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more
- © UX Strategy & Digital Branding